Evaluating the Journey of Amanitin ADC Development Contextualised with HDP-101 Phase I/ II Clinical Data to Lay the Path for ADC Payload Differentiation

• Laying out amanitin-based ADC as promising approach to overcoming drug resistance through differentiated payload mechanism of action
• Showcasing phase I/II dose escalation data of HDP-101: clinical performance and excellent safety and tolerability
• Explaining lessons learned across opportunities and hurdles of bringing a novel ADC payload to the clinic

Speakers:

Andras Strassz

Chief Medical Officer

Heidelberg Pharma